共查询到20条相似文献,搜索用时 15 毫秒
1.
Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. 总被引:12,自引:0,他引:12
下载免费PDF全文
![点击此处可从《Annals of surgery》网站下载免费的PDF全文](/ch/ext_images/free.gif)
S Fujimoto R D Shrestha M Kokubun M Ohta M Takahashi K Kobayashi S Kiuchi K Okui T Miyoshi N Arimizu et al. 《Annals of surgery》1988,208(1):36-41
Fifteen patients with far-advanced gastric cancer were given surgical treatment followed by intraperitoneal hyperthermic perfusion (IPHP) with mitomycin C (MMC) and misonidazole (MIS), a thermosensitizing drug. Immediately after extensive resection of the abdominal tumors, a 2-hour IPHP was performed at the inflow temperature of 44.7 to 48.7 C, using equipment designed for treatment of cancerous peritoneal seeding as a closed circuit, and under hypothermic general anesthesia at 30 to 31 C. In nine of the 15 patients with peritoneal seeding and/or ascites, cancerous ascites was absent after this treatment. In all cases, repeated cytologic examinations of the lavage from Douglas's pouch were negative. The postoperative courses were uneventful except for Patients 1 and 10, in whom slight leakage occurred. All patients were discharged and are in good health at the time of this writing, 7.2 +/- 4.6 months after the treatment. The Case 4 Patient recently died in a traffic accident. In all patients, transient hepatic dysfunction and hypoproteinemia occurred after the operation. This extensive surgery combined with IPHP using MMC and MIS was well tolerated and is a safe antitumor treatment for gastric cancer with peritoneal dissemination. Neurotoxicity due to MIS was nil. 相似文献
2.
目的研究胃癌术后腹腔热灌注化疗联合静脉化疗的治疗效果。方法140例胃癌根治术后患者随机分为腹腔热灌注组(n=72)和静脉化疗组(n=68)。腹腔热灌注组患者在静脉化疗同时应用腹腔热灌注化疗,观察两组术后并发症、不良反应、术后生存率及腹腔复发率。结果两组在术后并发症及不良反应无显著性差异。术后3、5年生存率腹腔热灌注组和静脉化疗组分别为86.1%、60.2%和58.3%、29.4%(P<0.05);术后3、5年腹腔复发率分别为5.6%、27.8%和20.6%、53%(P<0.05)。结论胃癌术后腹腔热灌注联合静脉化疗可有效控制复发和转移,提高胃癌术后病人的生存率和生存质量。 相似文献
3.
Positive results of combined therapy of surgery and intraperitoneal hyperthermic perfusion for far-advanced gastric cancer. 总被引:10,自引:0,他引:10
下载免费PDF全文
![点击此处可从《Annals of surgery》网站下载免费的PDF全文](/ch/ext_images/free.gif)
S Fujimoto R D Shrestha M Kokubun K Kobayashi S Kiuchi C Konno M Ohta M Takahashi Y Kitsukawa M Mizutani et al. 《Annals of surgery》1990,212(5):592-596
To evaluate the clinical efficacy of intraperitoneal hyperthermic perfusion (IPHP) for far-advanced gastric cancer, particularly with peritoneal seeding, we investigated the survival times of 59 patients who underwent distal subtotal gastrectomy, total gastrectomy, or total gastrectomy combined with concomitant resection of some of the remaining intra-abdominal organs. In all the 30 patients given IPHP, no cancer cells were present posthyperthermically in the lavage from the Douglas pouch. The 30 patients given IPHP lived longer than the 29 patients not given IPHP (p = 0.001), with a 1-year survival rate of 80.4% in the former group compared to 34.2% in the latter. With respect to a comparison of survival time of patients with peritoneal seeding, 7 patients not given IPHP had a 6-month survival rate of 57.1% and did not survive more than 9 months, whereas 20 patients given IPHP had 1- and 2-year survival rates of 78.7% and 45.0%, respectively; here the difference was significant (p = 0.001). The IPHP and control groups without peritoneal metastasis included 10 and 22 patients, respectively, and the 1-year survival rates are 85.4% and 45.3%, respectively. The survival rates of the former exceeded those of the latter, with p = 0.015 by the generalized Wilcoxon test. Thus this combined therapy offers the promise of extended survival for patients with far-advanced gastric cancer. 相似文献
4.
细胞减灭术加腹腔热灌注化疗治疗胃癌腹膜转移癌 总被引:1,自引:0,他引:1
目的 观察细胞减灭术(CRS)加腹腔热灌注化疗(HIPEC)治疗胃癌腹膜转移癌(PC)的疗效和安全性.方法 取成年雄性新西兰大白兔42只,将VX2癌细胞注入胃窦部黏膜下,制成溃疡型胃癌PC模型,随机分为空白组(n=14)、单纯CRS组(n=14)、CRS+HIPEC组(n=14).种瘤后第8~9天行治疗,HIPEC药物为多西紫杉醇(10 mg/只)、卡铂(40 mg/只),42 ℃腹腔灌注30 min.主要疗效指标为生存期,次要疗效指标为体质量、生化指标及安全性.结果 模型制作成功率100%(42/42).空白组动物生存期18~30 d(中位数24 d);单纯CRS组20~40 d(中位数27 d);CRS+HIPEC组23~55 d(中位数46 d)(单纯CRS组比空白组比较,P>0.05;CRS+HIPEC组比单纯CRS组,P<0.01).与CRS组比较,HIPEC至少能使生存期延长70%.体质量变化趋势提示HIPEC可延缓肿瘤所致的体质量减轻.各组动物种瘤前、术前及术后第8天外周血细胞计数及血生化指标差异无统计学意义(P>0.05).结论 对胃癌PC大动物模型,CRS不能改善预后,而CRS+HIPEC能显著延长生存期,安全可行.Abstract: Objective To study the efficacy and safety of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) to treat rabbit model of gastric cancer with peritoneal carcinomatosis (PC).Methods VX2 tumor cells were injected into the gastric submucosa of 42 adult male New Zealand rabbits using a laparotomic implantation technique,to construct rabbit model of gastric cancer with PC.The rabbits were randomly divided into three groups:control group (n = 14),CRS group (n = 14),and CRS + HIPEC group (n = 14 ).The rabbits in control group were observed for natural course of disease progression.Treatments were initiated 8 or 9 days after inoculation of tumor cells,including optimal removal of tumor nodules in CRS group,and maximal removal of tumor nodules and heperthermic chemoperfusion in the CRS + HIPEC group with docetaxel (10 mg/rabbit ) and carboplatin (40 mg/rabbit) at 42 ℃ for 30 min.The primary endpoint was overall survival.The secondary endpoints were body weight,biochemistry,major organ functions and serious adverse events.Results The success rates of rabbit PC model were 100% (42/42).The clinicopathological feature of the model was similar to peritoneal carcinomatosis in human.Overall survival was 18-30 days ( median 24 days) in control group,20-40 days ( median 27 days) in CRS group,and 23-55 days ( median 46 days) in CRS plus HIPEC group ( CRS alone group VS control group,P > 0.05;CRS + HIPEC group vs pure CRS group,P < 0.01 ).As compared with CRS only or control groups,HIPEC could extend the overall survival by at least 70%.At the baseline,on the day of surgery and 7 days after surgery,the count of peripheral blood cells,liver and renal functions,and biochemistry parameters were all comparable.Serious adverse events occurred in 0 animal in control group,2 animals in CRS group including 1 animal died of anesthesia overdose and another 1died of postoperative hemorrhage,and 3 animals in CRS + HIPEC group including 1 animal died of anesthesia overdose,and 2 died of diarrhea 23 and 27 days after operation.Conclusion For rabbit model of gastric cancer PC,CRS alone could not bring benefit while CPS + HIPEC with docetaxel and cisplatin could significantly prolong the survival with a acceptable safety. 相似文献
5.
目的:分析进展期胃癌术中腹腔热灌注化疗的效果。方法:选取94例接受胃癌根治术的患者,按照随机数字表分为观察组及对照组,各47例,观察组接受术中腹腔热灌注化疗,对照组仅接受单纯根治性手术,对比两组患者的疗效和并发症情况。结果:观察组CR 8例,PR 26例,有效率72.3%;对照组CR 3例,PR 15例,有效率38.3%,观察组有效率显著高于对照组(P0.05)。2组患者术后均出现血液指标异常、发热、血压下降、心率上升及其他并发症,均经对症处理后在7 d内恢复正常,其各项指标异常、并发症发生率无明显统计学差异(P0.05)。观察组患者1年、2年及3年存活率分别为85.1%、57.4%及29.8%,均显著高于对照组(P0.05)。结论:进展期胃癌术中腹腔热灌注化疗较传统胃癌根治术具有更好的疗效,且无明显不良反应,疗效及安全性均可靠。 相似文献
6.
BACKGROUND: Peritoneal recurrence is a major cause of death in advanced gastric cancer. Although many kinds of chemotherapy intended to prevent peritoneal recurrence of gastric cancer have been evaluated, few have been successful. Few studies have assessed the clinical significance of continuous hyperthermic peritoneal perfusion in peritoneal recurrence. METHODS: From 1992 to 1999, a total of 124 patients with advanced gastric cancer with tumors invading deeper than the serosa but with no peritoneal metastasis underwent potentially curative gastrectomy and were enrolled in this study. Prophylactic continuous hyperthermic peritoneal perfusion (P-CHPP) was performed in 45 patients younger than 65 years old and without comorbidity who gave informed consent. Seventy-nine patients who did not meet the inclusion criteria represented the control group. After reconstruction of the alimentary tract, P-CHPP was carried out for 40 minutes with 150 mg cisplatin, 15 mg mitomycin C, and 150 mg etoposide in 5 to 6 L physiologic saline maintained at 42 degrees C to 43 degrees C. The surgical results, recurrent pattern, and postoperative morbidity were assessed by univariate and multivariate analysis. RESULTS: When compared with patients not undergoing P-CHPP, patients treated by P-CHPP had higher incidences of respiratory failure (73% vs 19%; P <.0001) and renal failure (7% vs 0%; P <.03). Neither 5-year survival (49% vs 56%) nor the patterns of recurrence (peritoneal, hematogenous, and lymphatic) were affected by P-CHPP. CONCLUSIONS: P-CHPP by our methods had no efficacy as prophylactic treatment for peritoneal recurrence induced by gastric cancer. New therapeutic strategies, such as chemosensitivity assessment, are necessary to obtain good therapeutic results with CHPP. 相似文献
7.
目的观察进展期胃癌根治术后早期给予奥沙利铂(L-OHP)行腹腔热灌注化疗(CHIP)的不良反应及疗效。方法将83例进展期胃癌随机分为CHIP组和对照组,应用SPSS13.0分析并发症、复发率、转移率和无瘤生存率。CHIP组共37例,术后第1天给予L-OHP 100 mg/m2行CHIP,1次/d,4次为1疗程。对照组46例给予常规处理。结果两组严重并发症发生率差异无统计学意义。CHIP组的2~3年无瘤生存率明显高于对照组,差异有统计学意义。结论进展期胃癌术后早期给予L-OHP行CHIP,对提高2~3年无瘤生存率有明显疗效,而且方法简单、安全、实用。 相似文献
8.
目的 探讨腹腔镜胃癌并腹膜转移姑息性切除术联合腹腔热灌注化疗的安全性与疗效.方法 回顾性分析2010年3月至2013年10月间在南方医科大学南方医院普通外科接受腹腔镜姑息性切除术后腹腔热灌注化疗(100 mg顺铂、1000 mg氟尿嘧啶、2000 ml生理盐水)的37例胃癌并腹膜转移患者的临床病理资料,观察患者近期疗效及不良反应发生情况.结果 18例患者获完全缓解,4例获部分缓解,8例疾病稳定,7例疾病进展.肿瘤总缓解率为59.5%(22/37),Kamofsky功能状态评价获显著改善者6例,改善者13例,稳定者10例,进展者8例,改善与稳定患者占78.4%(29/37).严重不良反应(Ⅲ/Ⅳ级)3例(8.1%),其中腹痛2例(Ⅲ级),恶心呕吐1例(Ⅲ级).结论 胃癌并腹膜转移腹腔镜姑息性切除术后应用顺铂联合氟尿嘧啶方案的腹腔热灌注化疗是安全的,对延缓肿瘤进展具有一定作用. 相似文献
9.
10.
目的 探讨顺铂(DDP)联合持续热灌注治疗胃癌腹腔种植转移的临床疗效.方法 2009年2月至2012年2月间治疗的84例胃癌腹腔种植转移患者,随机分为观察组和对照组,每组各42例.观察组采用DDP联合腹腔持续热灌注治疗,对照组采用单独DDP腹腔灌注治疗.观察并记录两组患者腹水控制情况、不良反应发生情况.对患者进行随访,统计生存情况.结果 观察组和对照组总有效率分别为71.4%和50.0%,两组比较差异有统计学意义(P<0.05).两组中位生存期分别为10.3个月和6.0个月.两组不良反应发生率差异无统计学意义(P>0.05).结论 DDP联合持续热灌注治疗胃癌腹腔种植转移的临床疗效好,不良反应少,值得临床上进一步推广. 相似文献
11.
Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: Randomized controlled study 总被引:28,自引:0,他引:28
Takashi Fujimura M.D. Yutaka Yonemura M.D. Keiichi Muraoka M.D. Hiroyuki Takamura M.D. Yasuo Hirono M.D. Hiroyuki Sahara M.D. Itasu Ninomiya M.D. Hisashi Matsumoto M.D. Kouichiro Tsugawa M.D. Gen-ichi Nishimura M.D. Kazuo Sugiyama M.D. Kouichi Miwa M.D. Itsuo Miyazaki M.D. 《World journal of surgery》1994,18(1):150-155
We performed continuous hyperthermic peritoneal perfusion (CHPP) or continuous normothermic peritoneal perfusion (CNPP) combined with cisplatin (CDDP) 300 mg/kg and mitomycin C (MMC) 30 mg/kg in an attempt to prevent peritoneal recurrence after surgery for gastric cancer. Twenty-two patients were treated with perfusion using about 10 liters of saline heated to 41° to 42°C (CHPP group); 18 patients were treated with saline heated to 37° to 38°C (CNPP group); and 18 patients underwent only gastric surgery without perfusion (control group) in a randomized control study. There were two deaths (9%) due to peritoneal recurrence in the CHPP group, four (22%) in the CNPP group, and four (22%) in the control group. The 1-, 2-, and 3-year survival rates were 95%, 89%, and 68%, in the CHPP group; 81%, 75%, and 51%, in the CNPP group; and 43%, 23%, and 23%, in the control group, respectively. There was a significant difference between the three survival curves by the log-rank test (p<0.01). This difference showed that CNPP and CHPP are both effective procedures for preventing peritoneal recurrence. The maximum concentrations in the perfusate of total and free CDDP with 300 mg administration were 12.2 and 10.1 g/ml, respectively, at the end of the perfusion, and the maximum concentrations of total and free CDDP in plasma were 2.1 and 1.0 g/ml, respectively. The maximum concentrations of MMC in perfusate and plasma with 30 mg administration were 1.00 and 0.05 g/ml, respectively, which are intraperitoneally cytotoxic but systemically safe concentrations.
Resumen En pacientes sometidos a cirugía por cáncer gástrico hemos realizado perfusión peritoneal hipertérmica continua (PPHC) o perfusión peritoneal normotérmica continua (PPNC) combinada con cisplatino (CCDP) en dosis de 300 mg/cuerpo y mitomicina C (MMC) en dosis de 30 mg/cuerpo con miras a prevenir la recurrencia peritoneal. Veintidós pacientes fueron tratados con perfusión de alrededor de 10 litros de solución salina calentada a 41–42°C (grupo PPHC); 18 pacientes fueron tratados con solución salina calentada a 37–38°C (grupo PPNC); y 18 pacientes fueron sometidos a cirugía gástrica solamente, sin perfusión, los cuales constituyeron el grupo de control. El estudio fue randomizado. Las muertes por recurrencias peritoneales fueron dos (9%) en el grupo PPHC, cuatro (22%) en el grupo PPNC y cuatro (22%) en el grupo control. Las tasas de sobrevida a uno, dos y tres años fueron 95%, 89% y 68% en el grupo PPHC; 81%, 75% y 51% en el grupo PPNC; y 43%, 23% y 23% en grupo control, respectivamente. Se encontró una diferencia significativa en las tres curvas de sobrevida en la prueba de log-rank (p<0.01). La significativa diferencia hallada entre las tres curvas de sobrevida demuestran que, no sólo la perfusión intraperitoneal combinada con quimioterapia (PPNC) sino también la hipertermia intraperitoneal (PPHC), son procedimientos efectivos para la prevención de la recurrencia peritoneal. Las concentraciones máximas del CCDP total y libre en el líquido de perfusión en el régimen de 300 mg fue 12.2 y 10.1 g/ml al final de la perfusión. Las máximas concentraciones plasmáticas de CDDP total y libre fueron 2.1 y 1.0 g/ml al final de la perfusión. Las concentraciones máximas de MMC en el líquido de perfusión y en el plasma en regímenes por debajo de 30 mg fueron 1.0 y 0.05 g/ml. Tales resultados demuestran concentraciones intraperitoneales citotóxicas pero sistémicamente seguras.
Résumé Nous mettons en place une perfusion intrapéritonéale hyper (PPHC) ou isothermique continue (PPNC), associée à une chimiothérapie combinée (cisplatine (CDDP) à la posologie de 300 mg/Kg et mitomycine C (MMC) à la posologie de 30 mg/Kg) dans le but de prévenir les récidives péritonéales après chirurgie pour cancer gastrique. Dans une étude randomisée, 22 patients ont été traités par perfusions péritonéale avec 10 liters de sérum physiologique chauffé à 41–42°C (PPHC), 18 ont été traités avec du sérum à 37°C (PPNC) et 18 ont été opérés de leur cancer gastrique sans perfusion postopératoire (groupe contrôle (22%)). Les survies à 1, 2 et 3 ans étaient de 95, 89 et 68%, respectivement dans le groupe PPHC, de 81, 75 et 51% dans le groupe PPNC et de 43, 23 et 23% dans le groupe contrôle. Les trois courbes de survie différaient de façon significative (logrank p<0.01). Ces différences montrent que non seulement la perfusion intrapéritonéale associée à la chimiothérapie mais aussi l'hyperthermie intrapéritonéale sont efficaces pour prévenir la récidive péritonéale. après résection gastrique pour cancer. Les concentrations maximales globales et isolées de CDDP étaient de 12.2 et de 10.1 g/ml à la fin de la perfusion. Les concentrations plasmatiques maximales de MMC globales et isolées étaient de 1.00 et de 0.05 g/ml., respectivement. Ces résultats cliniques favorables démontrent que les concentrations obtenues ainsi ne sont pas nocives.相似文献
12.
Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer 总被引:13,自引:0,他引:13
Jason?J.?Hall Brian?W.?Loggie Perry?Shen Staci?Beamer L.?Douglas?Case Richard?McQuellon Kim?R.?Geisinger Edward?A.?Levine
Peritoneal carcinomatosis is a common and universally fatal sequelae of gastric carcinoma. Treatment of peritoneal carcinomatosis
from appendiceal and colorectal sources with intraperitoneal hyperthermic chemotherapy (IPHC) combined with aggressive cytoreductive
surgery has been shown to be effective. There are few data on this treatment modality for carcinoma of the stomach. This study
evaluates cytoreductive surgery and IPHC with peritoneal carcinomatosis from gastric carcinoma. Thirty-four patients with
peritoneal carcinomatosis due to gastric carcinoma underwent gastric resection with cytoreductive surgery followed by IPHC
with mitomycin C. A control group consisting of 40 contemporaneous patients, who underwent radical gastrectomy without extended
nodal resection, was identified through the tumor registry. Despite more advanced disease in the IPHC group compared to the
control group (P < 0.001), overall survival in the two groups was similar. Proportional-hazards regression analysis shows that only resection
status is significantly correlated with improved survival (P = 0.0068). Within the IPHC group, patients who underwent an R0/R1 resection had increased survival times (11.2 vs. 3.3 months,
P = 0.015) vs. those who underwent R2 resection. The group who had an R0/R1 resection had 1- and 2-year survival rates of 45%
and 45% compared to 16% and 8%, respectively, in the R2 group. Cytoreductive surgery and IPHC is a modality with limited potential
for the treatment of peritoneal carcinomatosis from gastric carcinoma. Careful patient selection for this procedure is imperative,
and patients in whom an R0/R1 resection can be achieved are the best candidates. 相似文献
13.
目的 探讨肿瘤细胞减灭术联合腹腔热灌注化疗术(HIPEC)患者术后肺部并发症(PPCs)的危险因素,并构建列线图和单变量偏依赖图。
方法 收集2019年1月至2020年6月行肿瘤细胞减灭术联合腹腔热灌注化疗298例患者的临床资料,男122例,女176例,年龄18~80岁,BMI>18 kg/m2,ASA Ⅰ—Ⅲ级。采用逐步回归分析筛选PPCs的影响因素,建立Logistic回归模型并绘制列线图。
结果 有106例(35.6%)患者发生PPCs。逐步回归分析显示,手术时间(OR=1.383, 95%CI 1.022~1.943)、失血量(OR=1.003, 95%CI 1.001~1.005)、红细胞输注量(OR=0.997, 95%CI 0.994~0.999)、进行液体管理时参考的每搏变异度(SVV)值(OR=0.034, 95%CI 0.009~0.089)是PPCs的影响因素。将上述影响因素纳入Logistic回归模型构建列线图,R2=0.912;拟合优度检验χ2=10.673,P=0.2209;C-Index=0.991;准确度=0.9799;Kappa=0.9563;F1值=0.972。
结论 肿瘤细胞减灭术联合HIPEC患者PPCs的影响因素为手术时间、失血量、红细胞输注量和SVV值。列线图预测模型具有良好的区分度与准确度,能很好地运用于肿瘤细胞减灭术联合HIPEC患者PPCs的预测。 相似文献
14.
15.
术中腹腔内温热灌注化疗在胃癌治疗中的应用 总被引:2,自引:0,他引:2
目的探讨术中腹腔内温热灌注化疗对胃癌术后腹腔种植转移和生存期的影响。方法将212例进展期胃癌根治性切除术后患者随机分成观察组92例,术中予以腹腔温热灌洗化疗(丝裂霉素30mg、顺铂100mg溶于蒸馏水2000ml中,加温至43℃~45℃,灌入腹腔保留30min后吸尽)和术后氟尿嘧啶(5-FU)10~15mg/kg、丝裂霉素(MMC)0.1~0.15mg/kg、阿霉素(ADM)0.5~1mg/kg静脉化疗,每周1次,2~3次为1疗程;对照组120例,术中用蒸馏水2000ml常规冲洗,术后按上述方法单纯静脉化疗。对两组患者术后腹腔种植转移率及1、3、5年生存率进行比较。结果观察组与对照组术后2年内腹腔种植转移率分别为14.1%和37.5%(P<0.01)。观察组术后1、3和5年生存率分别为98.9%、68.5%和52.2%;对照组为95.0%、56.7%和37.5%,两组3年和5年生存率差异有统计学意义(P<0.05)。结论术中温热灌注化疗具有杀灭腹腔游离癌细胞的作用,对进展期胃癌根治术后腹腔种植转移复发有较好的防治作用,能明显提高患者术后生存率。 相似文献
16.
Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin 总被引:11,自引:0,他引:11
No standard effective treatment exists for peritoneal carcinomatosis of gastrointestinal origin. The pharmacokinetic advantage of intraperitoneal chemotherapy and the synergy of heat and certain anticancer agents have prompted researchers to investigate intraperitoneal hyperthermic chemotherapy in treating disseminated peritoneal cancers. We have conducted a large Phase II trial to determine the safety and efficacy of aggressive cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IPHC) in treating peritoneal carcinomatosis of gastrointestinal origin. Patients with disseminated peritoneal carcinomatosis of gastrointestinal origin with or without malignant ascites were eligible. After aggressive surgical debulking, patients were administered a 2-hour heated (40.5 degrees C) intraperitoneal perfusion with mitomycin C. The major response variable monitored was overall survival. Patients were assessed for toxicity after IPHC administration using the National Cancer Institute Common Toxicity Criteria. Eighty-four patients with peritoneal carcinomatosis of gastrointestinal origin were evaluated for survival and toxicity (colon, n = 38; appendix, n = 22; stomach, n = 19; other gastrointestinal, n = 5). Thirty-nine (46%) patients had malignant ascites at the time of therapy. The operative mortality (30-day) was 6 per cent. Hematologic toxicity was the most common toxicity but was of mild to moderate severity (7 and 4% of patients had grade 3/4 white blood cell or platelet toxicity, respectively). The overall median survival was 14.3 months. The median survival of patients with peritoneal carcinomatosis of appendiceal, colorectal, and gastric origins were 31.1+, 14.6, and 10.1 months, respectively. Significant differences in median survival were seen in patients without and with malignant ascites (27.7 vs 7.6 months; P = 0.0004) and R0/R1 (complete gross tumor resection) versus R2 (gross residual tumor) surgical resection status (28.5+ vs 10.8 months, P = 0.0002). These data suggest that aggressive cytoreductive surgery with IPHC using mitomycin C is safe and effective in treating peritoneal carcinomatosis of gastrointestinal origin. Additional studies and broader applications of this treatment are encouraged. 相似文献
17.
淋巴、血液和种植转移是恶性肿瘤的基本特性.针对胃肠道肿瘤转移的治疗,可清晰看到3个阶段,即针对淋巴结转移的诊断分期和治疗体系,针对血液包括肝、肺转移的诊断评估和治疗体系,针对腹膜种植转移的诊断评估和治疗体系.我国腹膜转移诊治相关研究起步晚,目前仍是临床肿瘤治疗的难题之一[1]. 相似文献
18.
��ǻ�Ȼ��ƶԷ���θ�������������ٴ����� 总被引:9,自引:0,他引:9
目的 探讨进展期胃肠道癌手术切除后腹腔复发转移的防治方法。方法 对53例进展期胃肠道癌病人分组行围手术期持续腹腔温热化疗,并对其化疗术后1、2、3年生存率对照研究。结果 27例病人施腹腔化疗后1、2、3年生存期分别为88.46%,80.76%,69.23%明显高于对照组的84.61%,61.5%及46.2%,且并发症与副作用无差异。结论 腹腔温热化疗对进展期胃肠道癌术后复发良好的防治作用。 相似文献
19.
腹腔热灌注化疗是防治腹腔恶性肿瘤,尤其胃癌术后腹腔复发和肝转移的一项重要措施,其综合利用局部化疗、热疗和大容量化疗液对腹腔的机械灌洗作用,具有药代动力学及流体动力学优势,能有效清除游离癌细胞及微小癌灶,防治术后腹腔转移和肝转移. 相似文献